Docetaxel - Starpharma

Drug Profile

Docetaxel - Starpharma

Alternative Names: Dendrimer docetaxel; DEP™-Docetaxel; DTX-SPL8783

Latest Information Update: 06 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Starpharma
  • Developer Monash University; Starpharma
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 30 Sep 2015 Pharmacodynamics data from preclinical trials in Solid tumours released by Starpharma
  • 22 Jan 2014 Phase-I clinical trials in Solid tumours in Australia (IV)
  • 19 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top